Physician profile
Malcolm Purdy
NPI 1679535827
$3,099.43
in general payments reported to CMS, 2019-2025
40 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $119 · 2021: $37.93 · 2022: $170 · 2023: $307 · 2024: $910 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.99 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $360.75 | 2019-2025 | |
| Gilead Sciences, INC. | $283.57 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $271.90 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Pfizer INC. | $153.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $137.06 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $126.14 | 2024-2025 | |
| Seagen INC. | $124.78 | 2021-2023 | Adcetris |
| Puma Biotechnology, INC. | $108.91 | 2019-2025 | |
| Kite Pharma, INC. | $106.77 | 2020-2025 | Yescarta |
| Genzyme Corporation | $104.03 | 2019-2025 | |
| Abbvie INC. | $102.88 | 2024-2025 | |
| Genentech USA, INC. | $97.97 | 2019-2024 | Columvi, Polivy, Lunsumio |
| Array Biopharma INC | $91.48 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Merck Sharp & Dohme LLC | $90.84 | 2019-2025 | Keytruda, Welireg |
| Incyte Corporation | $86.10 | 2020-2024 | Jakafi, Monjuvi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $83.21 | 2023-2025 | Reblozyl |
| Janssen Biotech, INC. | $74.65 | 2021-2024 | Erleada |
| Astellas Pharma US INC | $52.93 | 2019-2025 | Xtandi |
| Regeneron Healthcare Solutions, INC. | $52.26 | 2024 | Libtayo |
| Exelixis INC. | $50.14 | 2024-2025 | Cabometyx |
| Eisai INC. | $45.18 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.91 | 2019 | |
| Stemline Therapeutics INC. | $38.94 | 2024-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $38.03 | 2019-2024 | Alunbrig |
| Glaxosmithkline, LLC. | $32.33 | 2024-2025 | Ojjaara |
| Taiho Oncology, INC. | $32.24 | 2024-2025 | |
| Sobi, INC | $32.10 | 2024 | |
| Emd Serono, INC. | $31.14 | 2024 | |
| Caris Mpi, INC. | $29.61 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $25.71 | 2024 | |
| Agios Pharmaceuticals, INC. | $24.99 | 2024 | |
| Aveo Pharmaceuticals, INC. | $24.31 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.11 | 2019 | |
| Genmab U.S., INC. | $21.77 | 2024 | Epkinly |
| Beigene USA, INC. | $21.02 | 2023 | Brukinsa |
| Jazz Pharmaceuticals INC. | $17.77 | 2023 | Zepzelca |
| Rigel Pharmaceuticals, INC. | $16.53 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| X4 Pharmaceuticals, INC. | $15.38 | 2025 | Xolremdi |
| Amgen INC. | $14.48 | 2019 | |
| Verastem, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Purdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.